These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11514956)

  • 1. Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2-treated human immunodeficiency virus-positive subjects.
    Caggiari L; Zanussi S; Crepaldi C; Bortolin MT; Caffau C; D'Andrea M; De Paoli P
    Cytometry; 2001 Aug; 46(4):233-7. PubMed ID: 11514956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics.
    Marchetti G; Meroni L; Molteni C; Bandera A; Franzetti F; Galli M; Moroni M; Clerici M; Gori A
    AIDS; 2004 Jan; 18(2):211-6. PubMed ID: 15075538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART.
    Martinez-Mariño B; Shiboski S; Hecht FM; Kahn JO; Levy JA
    AIDS; 2004 Oct; 18(15):1991-9. PubMed ID: 15577620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
    Dybul M; Hidalgo B; Chun TW; Belson M; Migueles SA; Justement JS; Herpin B; Perry C; Hallahan CW; Davey RT; Metcalf JA; Connors M; Fauci AS
    J Infect Dis; 2002 Jan; 185(1):61-8. PubMed ID: 11756982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy.
    Hengge UR; Borchard C; Esser S; Schröder M; Mirmohammadsadegh A; Goos M
    AIDS; 2002 Jan; 16(2):151-60. PubMed ID: 11807298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2.
    Zanussi S; Simonelli C; Bortolin MT; D'Andrea M; Crepaldi C; Vaccher E; Nasti G; Politi D; Barzan L; Tirelli U; De Paoli P
    Clin Exp Immunol; 1999 Jun; 116(3):486-92. PubMed ID: 10361239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection.
    Martinez-Mariño B; Ashlock BM; Shiboski S; Hecht FM; Levy JA
    J Clin Immunol; 2004 Mar; 24(2):135-44. PubMed ID: 15024180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy.
    Sriram U; Wong M; Caillier SJ; Hecht FM; Elkins MK; Levy JA; Oksenberg JR; Baranzini SE
    AIDS Res Hum Retroviruses; 2007 May; 23(5):741-7. PubMed ID: 17531001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
    Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A
    J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8 apoptosis may be a predictor of T cell number normalization after immune reconstitution in HIV.
    Lewis DE; Gross KL; Diez MM; Martinez ML; Lukefahr HN; Kozinetz CA; Arduino RC
    J Transl Med; 2007 Jan; 5():9. PubMed ID: 17263884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
    Al-Harthi L; Voris J; Du W; Wright D; Nowicki M; Frederick T; Landay A; Kovacs A
    J Infect Dis; 2006 May; 193(9):1202-10. PubMed ID: 16586355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients.
    Lempicki RA; Kovacs JA; Baseler MW; Adelsberger JW; Dewar RL; Natarajan V; Bosche MC; Metcalf JA; Stevens RA; Lambert LA; Alvord WG; Polis MA; Davey RT; Dimitrov DS; Lane HC
    Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13778-83. PubMed ID: 11095734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART.
    Romiti ML; Cancrini C; Castelli-Gattinara G; Di Cesare S; Ciaffi P; Bernardi S; De Gasperi MR; Halapi E; Rossi P
    AIDS; 2001 Nov; 15(16):2075-84. PubMed ID: 11684926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells.
    Sereti I; Martinez-Wilson H; Metcalf JA; Baseler MW; Hallahan CW; Hahn B; Hengel RL; Davey RT; Kovacs JA; Lane HC
    Blood; 2002 Sep; 100(6):2159-67. PubMed ID: 12200381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients--effects of antiretroviral therapy.
    Colle JH; Moreau JL; Fontanet A; Lambotte O; Joussemet M; Jacod S; Delfraissy JF; Thèze J
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):277-85. PubMed ID: 16810123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.
    Di Mascio M; Sereti I; Matthews LT; Natarajan V; Adelsberger J; Lempicki R; Yoder C; Jones E; Chow C; Metcalf JA; Sidorov IA; Dimitrov DS; Polis MA; Kovacs JA
    J Virol; 2006 Mar; 80(6):2665-74. PubMed ID: 16501076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy.
    Fleury S; Rizzardi GP; Chapuis A; Tambussi G; Knabenhans C; Simeoni E; Meuwly JY; Corpataux JM; Lazzarin A; Miedema F; Pantaleo G
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5393-8. PubMed ID: 10805798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell proliferation and apoptosis in HIV-1-infected lymphoid tissue: impact of highly active antiretroviral therapy.
    Dyrhol-Riise AM; Ohlsson M; Skarstein K; Nygaard SJ; Olofsson J; Jonsson R; Asjö B
    Clin Immunol; 2001 Nov; 101(2):180-91. PubMed ID: 11683577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
    Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.
    Kovacs JA; Vogel S; Metcalf JA; Baseler M; Stevens R; Adelsberger J; Lempicki R; Hengel RL; Sereti I; Lambert L; Dewar RL; Davey RT; Walker RE; Falloon J; Polis MA; Masur H; Lane HC
    Eur J Immunol; 2001 May; 31(5):1351-60. PubMed ID: 11465092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.